Boston Scientific (BSX) Raw Materials (2009 - 2026)

Boston Scientific (BSX) has 18 years of Raw Materials data on file, last reported at $928.0 million in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials rose 10.08% year-over-year to $928.0 million; the trailing twelve-month figure through Mar 2026 stood at $928.0 million (up 10.08% YoY), and the FY2025 full-year result was $849.0 million, up 3.66% from the prior year.
• Raw Materials improved to $928.0 million in Q1 2026, from $849.0 million in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $928.0 million in Q1 2026 to a low of $499.0 million in Q1 2022.
• A 5-year average of $743.2 million and a median of $818.0 million in 2024 frame the typical range for Raw Materials.
• Across the five-year window, Raw Materials soared 41.09% in 2023 and retreated 1.65% in 2025, its largest moves.
• Tracing BSX's Raw Materials over 5 years: stood at $548.0 million in 2022, then soared by 41.06% to $773.0 million in 2023, then increased by 5.95% to $819.0 million in 2024, then rose by 3.66% to $849.0 million in 2025, then climbed by 9.31% to $928.0 million in 2026.
• Business Quant data shows BSX's Raw Materials at $928.0 million in Q1 2026, $849.0 million in Q4 2025, and $849.0 million in Q3 2025.